MINDCURE Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research Jun 3, 2021
PsyBio Therapeutics Reports First Quarter 2021 Financial Results, Provides Shareholder Update and Announces Intention to… Jun 1, 2021
Cybin Announces Sponsorship of a Kernel Flow Feasibility Study to Measure Ketamine’s Psychedelic Effects on Cerebral… Jun 1, 2021
National Institutes of Health Director Praises Psychedelics and Medical Cannabis Research May 31, 2021
